Literature DB >> 3484761

The metabolism of C1 inhibitor and C1q in patients with acquired C1-inhibitor deficiency.

J Melamed, C A Alper, M Cicardi, F S Rosen.   

Abstract

The metabolism of 125I-labeled C1 inhibitor (C1INH) and C1q was studied in five patients with B cell lymphoproliferative disorders, C1INH deficiency, and angioedema. C1INH catabolism was markedly accelerated in these patients. The fractional catabolic rate (FCR) was 0.053 of the plasma pool per hour compared to that of normal subjects (0.025) or patients with hereditary angioneurotic edema (HANE) (0.035). The catabolism of two dysfunctional proteins Wel and Ta was studied. Protein Wel was catabolized at an accelerated rate (0.041) compared to that in patients with HANE (0.029) or in normal subjects (0.020). In contrast, the FCR of protein Ta was 0.012, which is similar to that in normal patients and in patients with HANE. The extravascular to plasma ratio (E/P) of the normal C1INH in patients was 1.55 compared to 0.60 in normal patients. This is consistent with the rapid extravascular sequestration of the C1INH. The synthesis rate of the C1INH was 0.29 mg/kg/hr in patients that is similar to that in control subjects. The metabolism of C1q was studied in two normal control subjects and three patients. The FCR of C1q was 0.051 in patients compared to 0.023 in control subjects. The E/P was increased in patients (2.8) compared to E/P in control subjects (0.6). The acquisition of C1INH deficiency results from increased consumption of C1INH in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484761     DOI: 10.1016/s0091-6749(86)80111-7

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

Review 2.  Angioedema. Pathogenesis, differential diagnosis, and treatment.

Authors:  Evangelo Frigas; Ugochukwu C Nzeako
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

3.  Acquired angioedema.

Authors:  Marco Cicardi; Andrea Zanichelli
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

4.  Acquired C1 inhibitor deficiency associated with systemic lupus erythematosus affecting the central nervous system.

Authors:  S Nakamura; M Yoshinari; Y Saku; K Hirakawa; C Miishima; K Murai; K Tokiyama; M Fujishima
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

5.  A nationwide study of acquired C1-inhibitor deficiency in France: Characteristics and treatment responses in 92 patients.

Authors:  Delphine Gobert; Romain Paule; Denise Ponard; Pierre Levy; Véronique Frémeaux-Bacchi; Laurence Bouillet; Isabelle Boccon-Gibod; Christian Drouet; Stéphane Gayet; David Launay; Ludovic Martin; Arsène Mekinian; Véronique Leblond; Olivier Fain
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.